Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
APS03118
i
Other names:
APS03118, APS-03118, APS 03118
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Applied Pharmaceutical Sci
Drug class:
RET inhibitor
Related drugs:
‹
selpercatinib (67)
pralsetinib (49)
TAS0953/HM06 (7)
RXDX-105 (5)
AST-487 (5)
FHND5071 (4)
EP0031 (4)
BOS-172738 (3)
TPX-0046 (2)
HG-6-63-01 (2)
SY-5007 (2)
TY-1091 (2)
XMD15-44 (2)
HSL468 (1)
HSL476 (1)
HSN608 (1)
LDD-2633 (1)
PLD-102 (1)
BTG-002814 (0)
SKI-G-801 (0)
HS269 (0)
JNJ-26483327 (0)
LOXO-260 (0)
PLD-101 (0)
HS-10365 (0)
SYHA1815 (0)
selpercatinib (67)
pralsetinib (49)
TAS0953/HM06 (7)
RXDX-105 (5)
AST-487 (5)
FHND5071 (4)
EP0031 (4)
BOS-172738 (3)
TPX-0046 (2)
HG-6-63-01 (2)
SY-5007 (2)
TY-1091 (2)
XMD15-44 (2)
HSL468 (1)
HSL476 (1)
HSN608 (1)
LDD-2633 (1)
PLD-102 (1)
BTG-002814 (0)
SKI-G-801 (0)
HS269 (0)
JNJ-26483327 (0)
LOXO-260 (0)
PLD-101 (0)
HS-10365 (0)
SYHA1815 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions (NCT05653869)
Phase 1
Applied Pharmaceutical Science, Inc.
Applied Pharmaceutical Science, Inc.
Recruiting
Phase 1
Applied Pharmaceutical Science, Inc.
Recruiting
Last update posted :
06/15/2023
Initiation :
02/06/2023
Primary completion :
04/01/2024
Completion :
04/01/2025
RET
|
RET fusion • RET mutation
|
APS03118
Share
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.